OMERS ADMINISTRATION Corp Purchases New Position in Edwards Lifesciences Corporation $EW

Key Points

• OMERS Administration Corp. bought 65,538 Edwards Lifesciences shares worth approximately $5.9 million in the second quarter, while other institutions also initiated positions. Institutional investors collectively own 79.46% of EW.
• Edwards Lifesciences exceeded quarterly expectations, reporting $0.78 EPS versus the $0.74 consensus and $1.74 billion in revenue, up 13.6% year over year. The company guided for third-quarter 2026 EPS of $0.71–$0.77 and full-year EPS of $2.95–$3.05.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $100.27 target price versus the stock’s $90.53 opening price. Several firms recently raised their targets, although insiders have sold shares in recent months.

OMERS ADMINISTRATION Corp purchased a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 65,538 shares of the medical research company's stock, valued at approximately $5,929,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Meiji Yasuda Asset Management Co Ltd. purchased a new position in shares of Edwards Lifesciences in the 2nd quarter worth approximately $4,832,000. Forefront Analytics LLC purchased a new stake in Edwards Lifesciences during the 2nd quarter valued at $557,000. Globeflex Capital L P bought a new stake in Edwards Lifesciences in the second quarter worth $182,000. Bank of Nova Scotia purchased a new position in Edwards Lifesciences during the second quarter worth $5,465,000. Finally, Compass Financial Management LLC bought a new position in Edwards Lifesciences during the second quarter valued at $32,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

EW stock opened at $90.53 on Tuesday. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The business has a 50-day moving average price of $89.30 and a 200 day moving average price of $84.74. The company has a market capitalization of $52.13 billion, a P/E ratio of 52.03, a PEG ratio of 2.25 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.70 billion. During the same period in the prior year, the business earned $0.67 EPS. The firm's quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EW has been the subject of several analyst reports. Leerink Partners upgraded shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and raised their target price for the stock from $87.00 to $101.00 in a report on Friday, July 24th. Truist Financial increased their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "hold" rating in a research report on Thursday, July 16th. Royal Bank Of Canada raised their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an "outperform" rating in a research note on Monday, July 13th. Piper Sandler restated an "overweight" rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Finally, Wall Street Zen cut Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Saturday, July 4th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $100.27.

Insider Activity

In related news, SVP Andrew M. Dahl sold 568 shares of the business's stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares of the company's stock, valued at $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 619 shares of the company's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president owned 40,034 shares of the company's stock, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 25,570 shares of company stock worth $2,219,390. Corporate insiders own 0.31% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source